Dr. Bloom is an internationally recognized pathologist with expertise in breast disease, digital pathology, immunohistochemistry and molecular pathology. He started his career at Rush University where he served several roles, including Director of Laboratory Operation and the Chief Information Officer for the Rush Cancer Institute. Dr. Bloom was instrumental in bringing digital pathology and image analysis tools to the clinic. Other positions include Chief Medical Officer (CMO) of Clarient. CMO for In-vitro Diagnostics at GE Healthcare, President and head of oncology and immunotherapy at Human Longevity and the CMO at RealmDx. Currently, he heads Pathology for Nucleai.
I have extensive experience in translational research and clinical trial design, especially in melanoma. My post-doctoral fellowships were at Cleveland Clinic and Indiana University respectively working in basic science labs on fundamental biologic processes. At Memorial Sloan Kettering Cancer Center, I trained with Drs David Spriggs, Carol Aghajanian and Paul Chapman gaining a broad understanding of experimental therapeutics. Over the next 7 years, at the Moffitt Cancer Center, A collaboration with Dr Heller has resulted in intratumoral IL12 as a treatment for melanoma. At UCSF, I lead the melanoma program and several early phase and melanoma specific clinical trials as well as collaborating with my colleagues Michael Rosenblum, Max Krummel and Jeff Bluestone at UCSF and with Meromot Singer and Arlene Sharpe at Harvard to analyse scRNA from melanoma patients. Im excited to collaborate with Susana Ortiz on her projects targeting nanoparticles for drug delivery in melanoma and novel kinase dependencies to Treat Metastatic NRAS Tumors
Mike Baratta currently serves as a Scientific Director for the Clinical Biomarker Innovation and Development group at Takeda Pharmaceuticals in Cambridge, MA. He received his B.A. from Loyola University of Chicago and a Masters Certificate in Applied Healthcare Project Management from Villanova University. Mike began his career as a member of the Global Drug Metabolism group at Pharmacia/G.D. Searle and transitioned to a Principal Scientist role with Pfizer after the closure of the merger. Prior to joining Takeda in 2013, he served as a Director on Nonclinical Development, Pharmacokinetics and Biometrics with Duck Flats Pharma. Mike is a member of several FNIH biomarker consortia, industry committees and serves as a standing member of the NIH/NSD-B grant application reviewer. Mike’s research focus is mass spectrometry focused analytical assay development and clinical validation of post translation biomarkers supporting patient characterization/stratification strategies.
John M Rossi is Vice President of Translational Medicine at Syncopation Life Sciences. John is an experienced Cell Therapy and Biotechnology leader with over 22 years of experience building robust clinical pharmacology, predictive biomarker, and correlative science processes to support oncology drug development. Most recently John was Senior Vice President of Research and Head of Translational Medicine at CERo Therapeutics. At CERo, John helped to guide Research, Process Development and Vector Sciences teams to advance preclinical initiatives. Prior to CERo, John was Senior Director and Head of Clinical Pharmacology at Kite, a Gilead Company. At Kite, John played an instrumental role in supporting global approvals of both Yescarta® and Tecartus® as well as IND approvals to advance investigational autologous T cell therapy products (KITE-363 and KITE-222). Among John’s notable achievements at Kite, he has represented the organization through numerous external scientific presentations and collaborative manuscripts with leading academic researchers in the cell therapy field. Significant scientific accomplishments include the discovery of novel metrics to characterize CAR T cells based on functionality and fitness, novel biomarker knowledge helping to elucidate CAR T-cell mechanism of action in humans, mechanistic information on CAR-related toxicities, novel insights into the biology of the tumor immune microenvironment, and the pivotal role of IL-15 in the context of CAR T-cell function. John began his tenure in clinical pharmacology and biomarker development at Amgen in 2002, leading global biomarker development for Phase III registrational trials in oncology (trebananib, AMG386), and preclinical, first-in-human and Phase II clinical trials (AMG780, AMG224 and AMG176). John has co-authored over 35 publications in the field of cell therapy and is co-inventor on 9 issued or submitted patents. John earned his Master of Science degree in Molecular Biology at Portland State University and his B.S. degree in Biology at Pitzer College in Claremont CA.
Dr. Pallavi Sachdev is a Senior Director in Clinical Pharmacology and Translational Medicine withing the Neurology Business Group at Eisai, a human health care (hhc) company. Dr. Sachdev drives the development and execution of the clinical biomarker strategy across a diverse neurology pipeline spanning programs in dementia, sleep and epilepsy. During her time at Eisai, Dr. Sachdev has increasingly focused on bridging the translational gap between the nonclinical and clinical teams and global biomarker research activities across all stages of clinical development (from early phase - first-in-human and proof-of-concept studies, to late stage/registrational studies) across therapeutic areas including oncology and neurology. Her responsibilities include alignment of drug and diagnostic strategies to deliver tailored therapeutics. Previously, Dr. Sachdev was a scientist at The Rockefeller University focusing on cancer signaling networks, stem cell biology and systems biology. Dr. Sachdev received her PhD in Biochemistry and Molecular Biology from Mount Sinai-New York University School of Medicine and her B.S. from Cornell University. She has co-authored numerous research publications in the fields of cancer signaling networks and cancer genomics and presented at international scientific conferences focusing on precision medicine and big data.
